Published in J Cardiovasc Pharmacol on January 01, 1987
Pharmacokinetics of intravenous cilazaprilat in normal volunteers. Br J Clin Pharmacol (1989) 0.98
The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension. Br J Clin Pharmacol (1989) 0.94
Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex. Br J Clin Pharmacol (1988) 0.87
Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients. Br J Clin Pharmacol (1989) 0.87
The pharmacokinetics and dose proportionality of cilazapril. Br J Clin Pharmacol (1989) 0.85
Cilazapril. A review. Drugs (1991) 0.83
The influence of food on the pharmacokinetics and ACE inhibition of cilazapril. Br J Clin Pharmacol (1989) 0.77
Cilazapril in congestive heart failure. A pilot study. Drugs (1991) 0.77
Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients. Br J Clin Pharmacol (1989) 0.75
Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man. Br J Clin Pharmacol (1989) 0.75
Pharmacokinetics of angiotensin converting enzyme inhibitors. Br J Clin Pharmacol (1989) 0.75
Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function. Br J Clin Pharmacol (1989) 0.75
Clinical pharmacology of cilazapril. Drugs (1991) 0.75
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med (1978) 5.04
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ (2001) 4.66
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med (1972) 3.73
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet (1977) 2.90
Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation (2000) 2.71
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol (1987) 2.36
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med (1979) 2.31
Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med (1972) 2.10
European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens (2010) 2.06
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet (1981) 1.99
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Improvement of chronic congestive heart-failure by oral captopril. Lancet (1979) 1.94
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol (1998) 1.92
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol (1981) 1.88
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther (1981) 1.88
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens (2001) 1.87
Knowledge, attitudes, and practices on hypertension in a country in epidemiological transition. Hypertension (1998) 1.87
Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med (1998) 1.83
An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med (1974) 1.82
Angiotensin II receptor antagonists. Lancet (2000) 1.82
Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension (1980) 1.81
Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens (2001) 1.80
Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet (1973) 1.78
Endothelial function in chronic congestive heart failure. Am J Cardiol (1992) 1.69
Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension (1992) 1.64
Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther (2007) 1.58
Fatal pancytopenia associated with the use of captopril. Ann Intern Med (1981) 1.54
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol (1983) 1.54
Biological properties of the angiotensin-converting enzyme inhibitor cilazapril. J Cardiovasc Pharmacol (1985) 1.51
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation (2008) 1.45
The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest (1970) 1.42
Does the activation of poly (ADP-ribose) synthetase mediate tissue injury in the sepsis induced by cecal ligation and puncture? Shock (2001) 1.41
Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest (2001) 1.41
Two-kidney, one clip and one-kidney, one clip hypertension in mice. Hypertension (1997) 1.41
[Antihypertensive agents used as first line agents: beta-blockers under pressure]. Rev Med Suisse (2006) 1.39
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol (1987) 1.37
Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation (1978) 1.30
Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia. Am J Physiol (1985) 1.29
Refining rodent husbandry: the mouse. Report of the Rodent Refinement Working Party. Lab Anim (1998) 1.28
Vasopeptidase inhibition and angio-oedema. Lancet (2000) 1.27
Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res (1975) 1.27
Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. Arterioscler Thromb Vasc Biol (1995) 1.25
Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension (1998) 1.25
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem (2000) 1.23
Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension (1990) 1.23
Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure. Lancet (1978) 1.23
Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. J Clin Invest (1972) 1.21
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther (1999) 1.20
Compliance with antihypertensive treatment: implications for practice. Blood Press (1997) 1.19
Hypertension of renal origin: evidence for two different mechanisms. Science (1971) 1.16
Proximal sodium reabsorption: An independent determinant of blood pressure response to salt. Hypertension (2000) 1.16
Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int (1999) 1.14
Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol (1973) 1.13
Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man. Drug Metab Dispos (1976) 1.13
Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest (2001) 1.13
Need for beta-blockade in hypertension reduced with long-term minoxidil. Br Med J (1978) 1.12
Isolated office hypertension: a prehypertensive state? J Hypertens (1996) 1.11
Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension (2000) 1.11
Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci U S A (2001) 1.11
Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. J Cardiovasc Pharmacol (2000) 1.07
Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension (1986) 1.05